Androgens and cardiovascular disease: Gender-related differences

Menopause International

Volumn 19, Issue 2, 2013, Pages 82-86

  Spoletini, Ilaria ^a   Caprio, Massimiliano ^a   Vitale, Cristiana ^a   Rosano, Giuseppe M C ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b Laboratory of Vascular Physiology IRCCS San Raffaele   (United Kingdom)

Author keywords

Androgens; Post menopausal women; Sex; Testosterone

Indexed keywords

ANDROGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

AGING; ANDROGEN BLOOD LEVEL; ANDROGEN THERAPY; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BLOOD VESSEL DIAMETER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FEMALE TO MALE TRANSSEXUAL; FUNCTIONAL STATUS; GLUCOSE METABOLISM; HEART FAILURE; HEART MUSCLE PERFUSION; HUMAN; HYPERTENSION; HYPOACTIVE SEXUAL DESIRE DISORDER; INSULIN RESISTANCE; METABOLIC SYNDROME X; MUSCLE STRENGTH; OBESITY; PERIPHERAL CIRCULATION; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SUPPLEMENTATION; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL PATCH; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84890191371     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1177/1754045313487720     Document Type: Review

References (47)

1. Spoletini I, Vitale C, Malorni W, et al. Sex differences in drug effects: interaction with sex hormones in adult life. Handb Exp Pharmacol 2012; 214: 91-105.
2. Franconi F, Carru C, Spoletini I, et al. A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. Ther Deliv 2012; 2: 1437-1453.
3. Mendelsohn ME and Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308: 1583-1587.
4. Ruige JB, Mahmoud AM, De Bacquer D, et al. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2012; 97: 870-875.
5. Rosano GM, Cornoldi A and Fini M. Effects of androgens on the cardiovascular system. J Endocrinol Invest 2005; 28: 32-38.
6. Tirabassi G, Gioia A, Giovannini L, et al. Testosterone and cardiovascular risk. Intern Emerg Med 2013; 8(Suppl 1): 65-69.
7. English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000; 21: 890-894.
8. Rosano GM, Sheiban I, Massaro R, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 2007; 19: 176-182.
9. Vitale C, Mendelsohn ME and Rosano GM. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol 2009; 6: 532-542.
10. Zheng HY, Li Y, Dai W, et al. Imbalance of testosterone/ estradiol promotes male CHD development. Biomed Mater Eng 2012; 22: 179-185.
11. Jones RD, Hugh Jones T and Channer KS. The influence of testosterone upon vascular reactivity. Eur J Endocrinol 2004; 151: 29-37.
12. McCrohon JA, Death AK, Nakhla S, et al. Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation 2000; 101: 224-226.
13. Villablanca AC, Jayachandran M and Banka C. Atherosclerosis and sex hormones: current concepts. Clin Sci (Lond) 2012; 119: 493-513.
14. McCredie RJ, McCrohon JA, Turner L, et al. Vascular reactivity is impaired in genetic females taking high-dose androgens. J Am Coll Cardiol 1998; 32: 1331-1335.
15. Worboys S, Kotsopoulos D, Teede H, et al. Evidence that parenteral testosterone therapy may improve endothelium- dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001; 86: 158-161.
16. Pasquali R, Vicennati V, Gambineri A, et al. Hormones and pathophysiology of obesity. Eat Weight Disord 2001; 6: 9-20.
17. Mammi C, Calanchini M, Antelmi A, et al. Androgens and adipose tissue in males: a complex and reciprocal interplay. Int J Endocrinol 2012; 2012: 789653.
18. Zmuda JM, Cauley JA, Kriska A, et al. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol 1997; 146: 609-617.
19. Montalcini T, Migliaccio V, Ferro Y, et al. Androgens for postmenopausal women's health?. Endocrine 2012; 42: 514-520.
20. Goh HH, Loke DF and Ratnam SS. The impact of longterm testosterone replacement therapy on lipid and lipoprotein profiles in women. Maturitas 1995; 21: 65-70.
21. Corona G, Rastrelli G, Vignozzi L, et al. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 2012; 25: 337-353.
22. Naessen T, Bergquist J, Lind L, et al. Higher endogenous estrogen levels in 70-year-old women and men: an endogenous response to counteract developing atherosclerosis?. Menopause 2012; 19: 1322-1328.
23. Bruck B, Brehme U, Gugel N, et al. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1997; 17: 2192-2199.
24. von Dehn G, von Dehn O, Volker W, et al. Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. Horm Metab Res 2001; 33: 110-114.
25. Alexandersen P, Haarbo J, Byrjalsen I, et al. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999; 84: 813-819.
26. Adams MR, Williams JK and Kaplan JR. Effects of androgens on coronary artery atherosclerosis and atherosclerosis- related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 1995; 15: 562-570.
27. Khaw KT. Comparison of the early outcome of acute myocardial infarction in women and men. N Engl J Med 1998; 338: 1543; author reply 4.
28. Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906.
29. Muller M, van der Schouw YT, Thijssen JH, et al. Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 2003; 88: 5076-5086.
30. Barrett-Connor E and Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. Bmj 1995; 311: 1193-1196.
31. Phillips GB, Pinkernell BH and Jing TY. Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol 1997; 17: 695-701.
32. Bernini GP, Sgro M, Moretti A, et al. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab 1999; 84: 2008-2012.
33. Chang AY, Abdullah SM, Jain T, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol 2007; 49: 109-116.
34. Sewdarsen M, Vythilingum S, Jialal I, et al. Abnormalities in sex hormones are a risk factor for premature manifestation of coronary artery disease in South African Indian men. Atherosclerosis 1990; 83: 111-117.
35. Phillips GB, Pinkernell BH and Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14: 701-706.
36. Barrett-Connor E and Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988; 78: 539-545.
37. Barrett-Connor E, Khaw KT and Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1986; 315: 1519-1524.
38. Hautanen A, Manttari M, Manninen V, et al. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis 1994; 105: 191-200.
39. Jeppesen LL, Jorgensen HS, Nakayama H, et al. Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol 1996; 16: 749-754.
40. D'Amico AV, Chen MH, Renshaw AA, et al. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer 2008; 113: 3290-3297.
41. Rosano GM. Androgens and coronary artery disease. A sex-specific effect of sex hormones? Eur Heart J 2000; 21: 868-871.
42. Yasui T, Matsui S, Tani A, et al. Androgen in postmenopausal women. J Med Invest 2012; 59: 12-27.
43. Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2012; 56: 1310-1316.
44. Sacca L. Heart failure as a multiple hormonal deficiency syndrome. Circ Heart Fail 2009; 2: 151-156.
45. Caminiti G, Volterrani M, Iellamo F, et al. Effect of longacting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54: 919-927.
46. Carson CC 3rd and Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med 2012; 9: 54-67.
47. Armstrong PW and Ezekowitz JA. Testosterone therapy in women with heart failure "why can't a woman be more like a man?". J Am Coll Cardiol 2012; 56: 1317-1319.